A single daily low dose of aspirin significantly reduced hepatic fat fraction and liver transaminase levels in a randomized trial in patients with metabolic-associated steatotic liver disease.
Early uncertainty about the safety of noninterferon antivirals in patients with liver cancer may have contributed to the slow acceptance of direct-acting antiviral agents in this population.
Omega-3 fatty acids downregulate expression of betacellulin in patients with NASH, providing a potential new avenue for prevention and treatment, a study has found.
A mathematical model forecasts a steady increase in liver disease burden, including a near doubling of liver cancers and a more than twofold increase in liver transplants.